IP Library › Granted Patent US 12,269,860
Granted Patent B2
US 12,269,860 · App. 17/746,664 · Granted Apr 8, 2025

Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR

Inventors: Martin Pulé (London, GB); Vijay Peddareddigari (London, GB); Christian Itin (London, GB)
Assignee: AUTOLUS LIMITED
C07K14/7051A61K39/4611A61K39/4631A61K39/464412A61K39/464413A61K39/464471A61K39/464495A61K48/005C07K14/71C07K14/715C12N15/86A61K2239/11A61K2239/31A61K2239/38A61K2239/47C07K2319/03C12N2740/16043C12N2800/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,269,860
App. No.
17/746,664
Granted
Apr 8, 2025
Kind
B2
Abstract

There is provided method for making a cell composition which comprises step of transducing a population of cells with a mixture of at least two viral vectors, wherein at least one vector comprises a nucleic acid sequence which encodes a chimeric antigen receptor (CAR); and wherein at least one vector comprises a nucleic acid encoding an activity modulator which modulates the activity of the CAR, of a cell expressing the CAR, or of a target cell. There is also provided a cell composition made by such a method and its use in the treatment of diseases such as cancer.

Claims (9)

1. A cytolytic immune cell expressing:

a) a chimeric antigen receptor (CAR) comprising an antigen-binding domain which binds disialoganglioside (GD2), wherein the CAR comprises a heavy chain variable region according to SEQ ID NO: 77 and a light chain variable region according to SEQ ID NO: 78;

b) a chimeric cytokine receptor (CCR) which binds IL-7, wherein the CCR comprises a first polypeptide comprising a heavy chain constant region according to SEQ ID NO: 32 and an IL-7 receptor α-chain endodomain according to SEQ ID NO: 41, and a second polypeptide comprising a human light kappa chain according to SEQ ID NO: 30 and a γ-chain receptor endodomain according to SEQ ID NO: 39;

c) a dominant negative SHP-2 (dnSH2) according to SEQ ID NO: 29; and

d) a monomeric dominant negative transforming growth factor β receptor II (dnTGFBRII) according to SEQ ID NO: 46.

2. A method for making the cell according to claim 1 , which comprises the step of introducing a nucleic acid or nucleic acids which encode a)-d) of claim 1 into a cytolytic immune cell ex vivo.

3. A pharmaceutical composition which comprises a plurality of cells according to claim 1 , together with a pharmaceutically acceptable carrier, diluent or excipient.

4. A method for treating cancer which comprises the step of administering the pharmaceutical composition according to claim 3 to a subject.

5. The method of claim 4 wherein the cancer is neuroblastoma.

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jul 30, 2026
From: AUTOLUS LIMITED
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 076084/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: PULÉ, MARTIN; PEDDAREDDIGARI, VIJAY; ITIN, CHRISTIAN
To: AUTOLUS LIMITED
Reel/Frame 061320/0862 →
Priority Claims (3)
GB 1903237 · Mar 8, 2019 · national
GB 1914216 · Oct 2, 2019 · national
GB 1916077 · Nov 5, 2019 · national
Continuity (2)
Continuation 17436673
Related Publication 20220364116A1 · Nov 17, 2022
References Cited (89)
US 10098911B2 · Pule et al. · 2018 [cited by applicant]
US 10478457B2 · Pule et al. · 2019 [cited by applicant]
US 10800854B2 · Pule et al. · 2020 [cited by applicant]
US 10800855B2 · Pule et al. · 2020 [cited by applicant]
US 10925943B2 · Pule et al. · 2021 [cited by applicant]
US 11103532B2 · Pule et al. · 2021 [cited by applicant]
US 11345734B2 · Pule et al. · 2022 [cited by applicant]
US 11479613B2 · Pulé et al. · 2022 [cited by applicant]
US 11701386B2 · Pulé et al. · 2023 [cited by applicant]
US 11959084B2 · Cordoba et al. · 2024 [cited by applicant]
US 20150023937A1 · Vera Valdes et al. · 2015 [cited by applicant]
US 20150093401A1 · Pule et al. · 2015 [cited by applicant]
US 20170291953A1 · Tamada et al. · 2017 [cited by applicant]
US 20170354682A1 · Pulé et al. · 2017 [cited by applicant]
US 20180064785A1 · Averback · 2018 [cited by applicant]
US 20180244797A1 · Pulé et al. · 2018 [cited by applicant]
US 20190015451A1 · Pulé et al. · 2019 [cited by applicant]
US 20190016820A1 · Pulé et al. · 2019 [cited by applicant]
US 20190023761A1 · Pule et al. · 2019 [cited by applicant]
US 20200048359A1 · Albelda et al. · 2020 [cited by applicant]
US 20200048618A1 · Cordoba et al. · 2020 [cited by applicant]
US 20200181624A1 · Jensen et al. · 2020 [cited by applicant]
US 20200222461A1 · Pulé et al. · 2020 [cited by applicant]
US 20200297766A1 · Pule et al. · 2020 [cited by applicant]
US 20210040227A1 · Pule et al. · 2021 [cited by applicant]
US 20210040228A1 · Pule et al. · 2021 [cited by applicant]
US 20210095003A1 · Pule et al. · 2021 [cited by applicant]
US 20210113618A1 · Pule et al. · 2021 [cited by applicant]
US 20210308240A1 · Pule et al. · 2021 [cited by applicant]
US 20220106602A1 · Cordoba et al. · 2022 [cited by applicant]
US 20220267404A1 · Pule et al. · 2022 [cited by applicant]
US 20220372105A1 · Ostertag · 2022 [cited by examiner]
US 20230133682A1 · Pulé et al. · 2023 [cited by applicant]
US 20240075066A1 · Pulé et al. · 2024 [cited by applicant]
US 20240156926A1 · Pulé et al. · 2024 [cited by applicant]
CN 107109421A · 2017 [cited by applicant]
CN 107406517A · 2017 [cited by applicant]
EP 3205720A1 · 2017 [cited by applicant]
WO WO2000063372A1 · 2000 [cited by applicant]
WO WO2013123061 · 2013 [cited by applicant]
WO WO2013153391A1 · 2013 [cited by applicant]
WO WO2015052538A1 · 2015 [cited by applicant]
WO WO2015075469A1 · 2015 [cited by applicant]
WO WO2015075470A1 · 2015 [cited by applicant]
WO WO2015132604A1 · 2015 [cited by applicant]
WO WO2015150771A1 · 2015 [cited by applicant]
WO WO2016030691A1 · 2016 [cited by applicant]
WO WO2016102965A1 · 2016 [cited by applicant]
WO WO2016090337A1 · 2016 [cited by applicant]
WO WO2016124930A1 · 2016 [cited by applicant]
WO WO2016135470A1 · 2016 [cited by applicant]
WO WO2016139487A1 · 2016 [cited by applicant]
WO WO2016193696A1 · 2016 [cited by applicant]
WO WO2017029512A1 · 2017 [cited by applicant]
WO WO2017147383A1 · 2017 [cited by applicant]
WO WO2017181148A2 · 2017 [cited by applicant]
WO WO2018045325A1 · 2018 [cited by applicant]
WO WO2018096361A1 · 2018 [cited by applicant]
WO WO2018115865A1 · 2018 [cited by applicant]
WO WO2018160731A1 · 2018 [cited by applicant]
WO WO2018193231A1 · 2018 [cited by applicant]
WO WO2019025800A1 · 2019 [cited by applicant]
WO WO2019053420A1 · 2019 [cited by applicant]
WO WO2019092442A1 · 2019 [cited by applicant]
WO WO2019116046A1 · 2019 [cited by applicant]
WO WO2019162695A1 · 2019 [cited by applicant]
WO WO2020025953A2 · 2020 [cited by applicant]
WO WO2020074868A1 · 2020 [cited by applicant]
WO WO2020183131A1 · 2020 [cited by applicant]
Baldan et al., “A Dominant Negative SHP-2 Which Abrogates PD-1 Signalling Pathways and Restores Function of Cytotoxic CAR T Cells,” Blood 130(1):3190 (2017). [cited by applicant]
Bedinger et al., “Development and characterization of human monoclonal antibodies that neutralize multiple TGF β isoforms,” MABS 8(2):389-404 (2016). [cited by applicant]
Bejcek et al., “Development and Characterization of Three Recombinant Single Chain Antibody Fragments (scFvs) Directed against the CD19 Antigen,” Cancer Res. 55:2346-2351 (1995). [cited by applicant]
Donnelly et al., “The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences,” Journal of General Virology 82:1027-1041 (2001). [cited by applicant]
Grada et al., “TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy,” Molecular Therapy—Nucleic Acids 2, e105, 11 pages (2013). [cited by applicant]
Haso et al., “Anti-CD22-Chimeric Antigen Receptors Targeting B Cell Precursor Acute Lymphoblastic Leukemia,” Blood 121(7):1165-1174 (2013). [cited by applicant]
Herbst et al., “B-Cell Depletion In Vitro and In Vivo with Afucosylated Anti-CD19 Antibody,” J. Pharmacol. Exp. Ther. 335:213-222 (2010). [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/GB2020/050535 dated Apr. 17, 2020. [cited by applicant]
Junghans et al., “Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response,” Prostate 76:1257-1270 (20… [cited by applicant]
Kansas et al., “Transmembrane Signals Generated Through MHC Class II, CD19, CD20, CD39, and CD40 Antigens Induce LFA-1-Dependent and Independent Adhesion in Human B Cells Through a Tyrosine Kinase-Dependent Pathway,” J.… [cited by applicant]
Kim et al., “An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative block TGF-β signaling,” J. Biol. Chem. 292(17)7173-7188 (2017). [cited by applicant]
Kloss et al., “Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation and Augments Prostate Cancer Eradication,” Mol. Ther. 26(7):1855-1866 (2018). [cited by applicant]
Leen et al., “Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor,” Molecular Therapy 22(6):1211-1220 (2014). [cited by applicant]
Mauldin et al., “The tyrosine phosphatase SHP-1 dampens murine Th17 development,” Blood 119(19):4419-4429 (2012). [cited by applicant]
Meeker et al., “A Unique Human B Lymphocyte Antigen Defined by a Monoclonal Antibody,” Hybridoma 3:305-320 (1984). [cited by applicant]
Newick et al., “Chimeric antigen receptor T-cell therapy for solid tumors,” Molecular Therapy—Oncolytics 3:16006, 7 pages (2016). [cited by applicant]
Nicholson et al., “Constructions and Characterisation of a Functional CD19 Specific Single Chain Fv Fragment for Immunotherapy of B Lineage Leukaemia and Lymphoma,” Mol. Immunol. 34:1157-1165 (1997). [cited by applicant]
Pezzutto et al., “CD19 Monoclonal Antibody HD37 Inhibits Anti-Immunoglobulin-Induced B Cell Activation and Proliferation,” J. Immunol. Baltim 138:2793-2799 (1987). [cited by applicant]
Roguska et al., “A comparison of two murine monoclonal antibodies humanized by CFR-grafting and variable domain resurfacing,” Protein Eng. 9:895-904 (1996). [cited by applicant]
Yazawa et al., “Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease,” Proc. Natl. Acad. Sci. 102:15178-15183 (2005). [cited by applicant]